Go back to the Europarl portal

Choisissez la langue de votre document :

  • bg - български
  • es - español
  • cs - čeština
  • da - dansk
  • de - Deutsch
  • et - eesti keel
  • el - ελληνικά
  • en - English (Selected)
  • fr - français
  • ga - Gaeilge
  • hr - hrvatski
  • it - italiano
  • lv - latviešu valoda
  • lt - lietuvių kalba
  • hu - magyar
  • mt - Malti
  • nl - Nederlands
  • pl - polski
  • pt - português
  • ro - română
  • sk - slovenčina
  • sl - slovenščina
  • fi - suomi
  • sv - svenska
Parliamentary questions
15 February 2017
E-001016-17
Question for written answer
to the Commission
Rule 130
Michał Marusik (ENF)

 Subject:  Medicinal products
 Answer(s) 

On 15 December 2016, the European Parliament adopted a resolution on the regulation on paediatric medicines (P8_TA(2016)0511).

In paragraph 9 of the resolution, Parliament calls on the Commission ‘to work as a matter of urgency on any possible regulatory changes that could […] in the meantime’ help improve the situation with regard to paediatric clinical research and accelerate paediatric drug development, in particular drugs for neonatology and childhood cancers.

In the light of the above: what steps have already been taken, or what steps does the Commission intend to take in the near future, in response to the resolution?

Original language of question: PL 
Last updated: 7 March 2017Legal notice